Kevin is currently Senior Vice President, Head of Global BD&L at Simcere Pharmaceutical Group. Kevin is an established Corporate Strategy, Business Development / M&A professional with over 30 years biopharmaceuticals experience. His responsibilities include close leadership of the Global BD&L team, Global Strategic Investments/Post Investment Management (PIM) and Global Alliance Management. Kevin is a Simcere Executive Management Team member.
Prior to joining Simcere, Kevin was Global Head of BD&L-External Alliances at Alcon, a division of Novartis. Prior to this he served for 9 years in various leadership roles in BD&L at Merck, having previously led CNS drug target validation for 12 years at Merck, Sharp & Dohme. Notable achievements in his R&D career include the identification and validation of the CGRP receptor, work that he extensively published and that formed the concept underpinning the new class of anti-migraine agents, both biologics and small molecules.
Kevin holds a Ph.D. degree in Neuropathology and RNA Virology from the University of Cambridge, and a B.Sc in Immunology from King’s College London.
Kevin’s office is located in Cambridge, MA.